volinact.com → eat → recipe pot chicken → what are protacs
Posted on by Remington Mack

What Are PROTACs?

Illustration of a PROTAC molecule binding to both an E3 ligase and a target protein

PROTACs (Proteolysis Targeting Chimeras) are small molecules that direct the cell's natural protein destruction machinery to degrade specific disease-causing proteins. They work by linking a target protein to an E3 ubiquitin ligase, marking the protein for degradation.

How PROTACs Work

PROTACs function through a three-step process:

  1. Binding: The PROTAC binds to both the target protein and an E3 ubiquitin ligase.
  2. Ubiquitination: The E3 ligase adds ubiquitin tags to the target protein, marking it for destruction.
  3. Degradation: The tagged protein is recognized and broken down by the proteasome, the cell's waste disposal system.

The PROTAC itself is recycled and can repeat the process, making it highly efficient.

Types of PROTACs

PROTACs can be categorized based on their structure and the E3 ligases they recruit:

Type E3 Ligase Recruited Example Target Protein
Peptide-based PROTACs VHL (von Hippel-Lindau) Estrogen receptor
Small-molecule PROTACs CRBN (Cereblon) BRD4 (a protein involved in cancer)
Clipping PROTACs Multiple E3 ligases Kinases and other enzymes

Each type has advantages depending on the target protein and the desired therapeutic effect.

Applications of PROTACs

PROTACs are primarily used in drug discovery to target proteins that are difficult to inhibit with traditional small-molecule drugs. For example, ARV-471, a PROTAC developed by Arvinas, targets the estrogen receptor for the treatment of breast cancer.

Researchers are also exploring PROTACs for neurodegenerative diseases, such as Alzheimer's, by targeting toxic proteins like tau or amyloid-beta.

Common Misconceptions

One common misconception is that PROTACs permanently disable proteins. In reality, they temporarily reduce protein levels, allowing the cell to regulate protein abundance dynamically.

Another myth is that PROTACs are only useful for cancer therapy. While they are widely studied for oncology, their applications extend to inflammatory diseases, infections, and genetic disorders.

A Real-World Example

In 2020, the first PROTAC-based drug, ARV-471, entered clinical trials for breast cancer. This drug specifically targets the estrogen receptor, reducing its levels in cancer cells and slowing tumor growth. The success of ARV-471 has paved the way for further research into PROTACs for other diseases.

PROTACs represent a new approach in drug discovery, offering a precise and efficient way to target and degrade disease-causing proteins. Their versatility and potential applications make them a promising tool in modern medicine.


Related Posts